fbpx Yourgene Health plc - Home
004-news.jpg
001-news.jpg
002-news.jpg
DSC00185r.jpg
003-news.jpg
previous arrow
next arrow

Please find below the latest news from Yourgene Health. We also share this news across social media networks.

  • 26 April 2022 - Directorate Change +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Directorate Change

    Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that after a five-year tenure, Adam Reynolds will step down from his position as Chairman, at the Company’s next Annual General Meeting (“AGM”). The Board is pleased to confirm that he will remain on the Board as a Non-executive Director.

    Dr John Brown CBE, currently a Non-executive Director

    Read More
  • 26 April 2022 - Full year trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Full year trading update

    Manchester, UK – 26 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides the following unaudited trading update for the year ended 31 March 2022 (“FY22”).

    FY22 performance in line with upgraded guidance

    Revenues for FY22 were £37.6m, up 105% on the previous year and in line with recently upgraded guidance.

    • Genomic Services (“GS”) revenues up 239% to £21.6m
  • Read More
  • 25 April 2022 - Strategic partnership extended with Ambry Genetics +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Strategic partnership extended with Ambry Genetics
    Expanding market access of technology

    Manchester, UK – 25 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the Company has extended its strategic partnership with Ambry Genetics (‘Ambry’), a leading US precision medicine company, with a new Genomic Services collaboration. The new agreement will allow both companies access to each other’s technology and assays, expanding market access and penetration

    Read More
  • 06 April 2022 - Capital Markets Day +

    Yourgene Health plc

    (“Yourgene”  or the “Company”)

    Capital Markets Day

    Manchester, UK – 6 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be holding a Capital Markets Day for investors on Tuesday 26 April 2022.
     
    The event will provide investors with a compelling opportunity to hear more from other senior members of the management team about the roadmap and growth plans for certain products and services, both in North
    Read More
  • 17 February 2022 - Successful CTDA desktop review +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Successful CTDA desktop review
    Approval for sale of Clarigene® SARS-CoV-2 Test in the UK

    Manchester, UK - 17 February 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that it has received confirmation from the UK Health Security Agency that the Clarigene® SARS-CoV-2 test (CE-IVD) (“Clarigene ® ”) has been approved under the requirements set out in the Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations

    Read More
  • 25 January 2022 - Directorate Change +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Directorate Change

    Manchester , UK - 25 January 2022 : Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces the appointment of Mary Tavener as a Non-executive Director (“NED”) and Chair of the Audit Committee at Yourgene with effect from today.

    Mary has extensive experience in the healthcare sector, having previously been Chief Financial Officer and board member of AIM listed Advanced Medical Solutions plc (“AMS”) for

    Read More
  • 19 January 2022 - Opening of new Yourgene Health Canada Inc. facilities +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Opening of new Yourgene Health Canada Inc. facilities
    Supporting future growth for Ranger ® Technology

    Manchester, UK – 19 January 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Health Canada Inc. will launch its new expanded facilities at 702 – 1515 Broadway Street, Port Coquitlam, Vancouver, BC V3C 6M2, today from 12:30 (PST).

    The opening will be led by Mayor Brad West, Mayor of Port

    Read More
  • 19 January 2022 - Agreement of new debt facility +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Agreement of new debt facility
    Silicon Valley Bank facility to provide non-dilutive funding for accretive growth opportunities

    Manchester, UK – 19 January 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the Company has entered into a new three-year £5m term loan facility (the “Facility”) with Silicon Valley Bank (“SVB”). The Facility will provide access to non-dilutive funding to enable the Group to capitalise

    Read More
  • 18 January 2022 - US partnership with EKF Diagnostics for NIPT and additional genomic tests +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    US partnership with EKF Diagnostics for NIPT and additional genomic tests
    Collaboration with EKF Diagnostics to use its accredited US laboratories for NIPT and Oncology testing

    Manchester, UK – 18 January 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has signed a strategic partnership agreement with EKF Diagnostics Holdings plc (“EKF”, AIM: EKF), a point-of-care business with accredited laboratory testing capabilities

    Read More
  • 17 January 2022 - Current year trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Current year trading update
    Further upgrade to full year revenue guidance following strong trading performance

    Manchester, UK – 17 January 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, provides an update on trading for the current financial year ending 31 March 2022.

    The strong trading performance seen in the first half of the year has continued into the second half. Yourgene's high throughput COVID-19 testing

    Read More
  • 23 Dec 21 - DHSC contract awarded to support COVID-19 Winter surge testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    DHSC contract awarded to support COVID-19 Winter surge testing
    Third contract awarded under PHE National Microbiology Framework Agreement

    Manchester, UK – 23 December 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that Yourgene Genomic Services ('YGS') has been awarded a contract for the provision of laboratory capacity to support the Winter Surge COVID-19 testing by the Department of Health & Social Care (DHSC),

    Read More
  • 14 December 2021 - UKHSA contract award +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    UKHSA contract award
    Contract for the provision of the genetic sequencing services

    Manchester, UK – 14 December 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that Yourgene Genomic Services ('YGS') has been awarded a contract for the provision of genetic sequencing services by the UK Health Security Agency (UKHSA), running until 31 March 2022.

    The contract for the provision of sequencing services is the second contract

    Read More
  • 14 December 2021 - Half-year Report +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    H1 revenues doubled year-on-year
    Full year revenues to exceed already upgraded market expectations

    Manchester, UK – 14 December 2021: Yourgene (AIM: YGEN), a leading integrated technologies and service group enabling the delivery of genomic medicine, announces its unaudited half-year report for the six months ended 30 September 2021 (“H1 FY22”). Unless otherwise stated, comparative data shown is for the six-month period ended 30 September 2020 (“H1

    Read More
  • 18 November 2021 - DPYD screening recommended in Spain +


    Yourgene Health plc
    (“Yourgene” or the “Company”)

    DPYD screening recommended in Spain
    Follows recommendations in Germany, Wales, England and Belgium

    Manchester, UK – 18 November 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, welcomes the publication in Clinical and Translational Oncology, titled: ‘Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fuoropyrimidines

    Read More
  • 28 October 2021 - Yourgene’s Ranger Technology to be presented at Labroots webinar +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene’s Ranger ® Technology to be presented at Labroots webinar

    Manchester, UK – 28 October 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Ranger® Technology, which was acquired with Coastal Genomics Inc in August 2020, will be presented by Yourgene’s strategic customer, Labcorp, at the Labroots 2021 Clinical Diagnostics and Research Virtual Symposium Event, taking place on Wednesday 10 November 2021.

    During

    Read More
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    Pregnant lady sitting at table with Laptop

    Media & Investor Relations
    Walbrook PR Ltd
    4 Lombard Street
    London
    EC3V 9HD
    yourgene@walbrookpr.com
    T : +44 (0)20 7933 8780

    Two business people looking at computer screen